- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05921994
Studio osservazionale, prospettico e multicentrico a lungo termine per raccogliere in una popolazione reale dati sul modello di trattamento di secukinumAb in pazienti adulti con idrosadenite suppurativa da moderata a grave. (ANIMA)
Studio osservazionale, prospettico, multicentrico a lungo termine per raccogliere in una popolazione reale dati sul modello di trattamento di secukinumAb in pazienti adulti con idrosadenite suppurativa (HS) da moderata a grave (ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Aachen, Germania, 52064
- Novartis Investigative Site
-
Ahaus, Germania, 48683
- Novartis Investigative Site
-
Annaberg-Buchholz, Germania, 09456
- Novartis Investigative Site
-
Bad Steben, Germania, 95138
- Novartis Investigative Site
-
Baden-Baden, Germania, 76530
- Novartis Investigative Site
-
Berlin, Germania, 12159
- Novartis Investigative Site
-
Berlin, Germania, 13595
- Novartis Investigative Site
-
Bielefeld, Germania, 33647
- Novartis Investigative Site
-
Bochum, Germania, 44791
- Novartis Investigative Site
-
Bonn, Germania, 53105
- Novartis Investigative Site
-
Brandenburg, Germania, 14776
- Novartis Investigative Site
-
Bremen, Germania, 28359
- Novartis Investigative Site
-
Buxtehude, Germania, 21614
- Novartis Investigative Site
-
Bückeburg, Germania, 31675
- Novartis Investigative Site
-
Chemnitz, Germania, 09117
- Novartis Investigative Site
-
Chemnitz, Germania, 09113
- Novartis Investigative Site
-
Cologne, Germania, 51065
- Novartis Investigative Site
-
Delitzsch, Germania, 04509
- Novartis Investigative Site
-
Dessau, Germania, 06847
- Novartis Investigative Site
-
Dorsten, Germania, 46282
- Novartis Investigative Site
-
Dortmund, Germania, 44137
- Novartis Investigative Site
-
Dresden, Germania, 01309
- Novartis Investigative Site
-
Düren, Germania, 52349
- Novartis Investigative Site
-
Emsdetten, Germania, 48282
- Novartis Investigative Site
-
Erlangen, Germania, 91054
- Novartis Investigative Site
-
Falkenberg, Germania, 04895
- Novartis Investigative Site
-
Falkensee, Germania, 14612
- Novartis Investigative Site
-
Freising, Germania, 85354
- Novartis Investigative Site
-
Geilenkirchen, Germania, 52511
- Novartis Investigative Site
-
Gera, Germania, 07548
- Novartis Investigative Site
-
Gernsbach, Germania, 76593
- Novartis Investigative Site
-
Gladbeck, Germania, 45964
- Novartis Investigative Site
-
Großenhain, Germania, 01558
- Novartis Investigative Site
-
Hamburg, Germania, 20246
- Novartis Investigative Site
-
Hamburg, Germania, 22143
- Novartis Investigative Site
-
Hanover, Germania, 30159
- Novartis Investigative Site
-
Haslach im Kinzigtal, Germania, 77716
- Novartis Investigative Site
-
Hofgeismar, Germania, 34369
- Novartis Investigative Site
-
Jena, Germania, 07743
- Novartis Investigative Site
-
Jülich, Germania, 52428
- Novartis Investigative Site
-
Karlsruhe, Germania, 76133
- Novartis Investigative Site
-
Kempen, Germania, 47906
- Novartis Investigative Site
-
Lübeck, Germania, 23538
- Novartis Investigative Site
-
Magdeburg, Germania, 39120
- Novartis Investigative Site
-
Magdeburg, Germania, 39104
- Novartis Investigative Site
-
Mainz, Germania, 55116
- Novartis Investigative Site
-
Marburg, Germania, 35043
- Novartis Investigative Site
-
Minden, Germania, 32429
- Novartis Investigative Site
-
Mönchengladbach, Germania, 41063
- Novartis Investigative Site
-
Neu Wulmstorf, Germania, 21629
- Novartis Investigative Site
-
Nuremberg, Germania, 90419
- Novartis Investigative Site
-
Oberasbach, Germania, 90522
- Novartis Investigative Site
-
Oelde, Germania, 59302
- Novartis Investigative Site
-
Peitz, Germania, 03185
- Novartis Investigative Site
-
Potsdam, Germania, 14469
- Novartis Investigative Site
-
Remscheid, Germania, 42897
- Novartis Investigative Site
-
Selters, Germania, 56242
- Novartis Investigative Site
-
Simmern, Germania, 55469
- Novartis Investigative Site
-
Soest, Germania, 59494
- Novartis Investigative Site
-
Stolberg, Germania, 52222
- Novartis Investigative Site
-
Unna, Germania, 59423
- Novartis Investigative Site
-
Wittlich, Germania, 54316
- Novartis Investigative Site
-
Wuppertal, Germania, 42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Germania, 79068
- Novartis Investigative Site
-
Rheinstetten, Baden-Wurttemberg, Germania, 76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt, Bavaria, Germania, 97437
- Novartis Investigative Site
-
Kulmbach, Bavaria, Germania, 95326
- Novartis Investigative Site
-
Lauf an der Pegnitz, Bavaria, Germania, 91207
- Novartis Investigative Site
-
Nuremberg, Bavaria, Germania, 90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal, Brandenburg, Germania, 16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Germania, 22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen, Lower Saxony, Germania, 49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen, Mecklenburg-Vorpommern, Germania, 18528
- Novartis Investigative Site
-
Kröpelin, Mecklenburg-Vorpommern, Germania, 18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld, North Rhine-Westphalia, Germania, 47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Germania, 55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Germania, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Germania, 04207
- Novartis Investigative Site
-
Leipzig, Saxony, Germania, 04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg, Saxony-Anhalt, Germania, 06886
- Novartis Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
Descrizione
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of patients receiving up-titration
Lasso di tempo: Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
Lasso di tempo: Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
Lasso di tempo: Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
Lasso di tempo: Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
Lasso di tempo: Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Lasso di tempo: Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
Lasso di tempo: Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Lasso di tempo: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Lasso di tempo: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Lasso di tempo: Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
Lasso di tempo: Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Lasso di tempo: Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CAIN457MDE01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .